EPISODE · Jan 9, 2012 · 8 MIN
Using BCR-ABL Transcript Levels After 3 Months of Therapy on Imatinib is the Best Way to Predict Long-Term Outcome for Patients with CML Treated with Imatinib
from Journal of Clinical Oncology (JCO) Podcast
The study by Marin et al is another milestone in our understanding how to manage CML patients on tyrosine kinase inhibitors.
Embed this episode
NOW PLAYING
Using BCR-ABL Transcript Levels After 3 Months of Therapy on Imatinib is the Best Way to Predict Long-Term Outcome for Patients with CML Treated with Imatinib
0:00
8:55
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Journal of Clinical Oncology (JCO) Podcast?
This episode is 8 minutes long.
When was this Journal of Clinical Oncology (JCO) Podcast episode published?
This episode was published on January 9, 2012.
Can I download this Journal of Clinical Oncology (JCO) Podcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!